

Large independent hospital in Southeastern United States adopts ASTar®

Q-linea AB (publ) (OMX: QLINEA) today announces the contract signing for ASTar adoption by a large independent health system in the Southeastern United States.

The facility is specialized in treating cancer and pediatric patients initiated an evaluation in 2025, which was previously communicated: [Q-linea announces the initiation of another US ASTar evaluation | Q-linea](#).

For more information, please contact:

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company's core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.

Q-linea's flagship technology, ASTar®, is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea is listed on Nasdaq Stockholm.

Attachments

[Large independent hospital in Southeastern United States adopts ASTar®](#)